Document And Entity Information Marketable Securities, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Exercise of stock options (in shares) Exercised, number of shares (in shares) Note 3 - Summary of Significant Accounting Policies ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Note 4 - Fair Value of Financial Instruments ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Note 6 - Prepaid Expenses Trading Arrangements, by Individual [Table] Note 7 - Accrued Expenses and Other Current Liabilities Material Terms of Trading Arrangement [Text Block] Note 9 - Stockholders' Equity and Common Stock Warrants Class of Stock [Domain] Note 10 - Stock-based Compensation Stock Financial Instrument [Axis] Note 11 - Segments Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Commercial paper us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Commercial paper Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details) Liquidity Disclosure [Text Block] The entire disclosure for the liquidity of the company. Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details) Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details) us-gaap_IncreaseDecreaseInAccountsReceivable Grant receivable Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details) Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details) Note 11 - Segments - Schedule of Segment Information (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Cash flows from operating activities: Cash flows from investing activities: us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Cash flows from financing activities: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by investing activities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_AssetsFairValueDisclosure Marketable securities Forfeited, weighted average exercise price (in dollars per share) Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Operating Segments [Member] us-gaap_LaborAndRelatedExpense Personnel costs, excluding stock-based compensation Accounting Policies [Abstract] Professional services Amount of asset related to consideration paid in advance for professional services that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Financial Instruments [Domain] US Treasury Securities [Member] US Government Debt Securities [Member] Deferred offering costs in accrued expenses Deferred offering costs in accounts payable The amount of debt offering costs that were incurred during a noncash or partial noncash transaction. Income Statement [Abstract] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Dues and memberships Amount of prepaid dues and memberships, classified as current. us-gaap_NumberOfReportableSegments Number of Reportable Segments Collaborative Arrangement Disclosure [Text Block] Segment Reporting [Text Block] us-gaap_ContractualObligation Contractual Obligation Prepaid expenses and other current assets Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Net loss Net loss Net loss Adjustments to reconcile net loss to net cash used in operating activities: Award Type [Axis] Segment Reporting [Table Text Block] us-gaap_PreferredStockValue Series A preferred stock $0.001 par value: 30,000,000 authorized at March 31, 2026 and December 31, 2025, 0 shares issued and outstanding at March 31, 2026 and December 31, 2025 us-gaap_Liabilities Total liabilities Plan Name [Axis] Plan Name [Domain] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Share based compensation expense us-gaap_AllocatedShareBasedCompensationExpense Stock-based compensation Consolidation Items [Axis] Cash and Cash Equivalent [Table] Cash and Cash Equivalents [Axis] Title and Position [Axis] Segment Reporting [Table] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets Condensed Balance Sheet Statement [Table] Stock-based compensation expense us-gaap_ShareBasedCompensation Consolidation Items [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-Based Payment Arrangement, Accelerated Cost Share-Based Payment Arrangement [Text Block] Series A Common Stock Warrants [Member] Series A Common Stock Warrants Changes in operating assets and liabilities: us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Preferred Stock, Shares Issued (in shares) Accounting Standards Update and Change in Accounting Principle [Table] Preferred Stock, Shares Outstanding (in shares) Reclassification [Table] Preferred Stock, Shares Authorized (in shares) Income Tax, Policy [Policy Text Block] Equity Incentive Plan 2015 [Member] Represents the information pertaining to the 2015 equity incentive plan. Preferred Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses and other current liabilities us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net (decrease) increase in cash and cash equivalents Series A Preferred Stock [Member] us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash equivalents New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Antidilutive Securities, Name [Domain] Concentration Risk, Credit Risk, Policy [Policy Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Net loss: Share-Based Payment Arrangement, Tranche One [Member] us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-Sale, Allowance for Credit Loss Statement [Table] Insurance Fair Value Hierarchy and NAV [Domain] Measurement Frequency [Domain] Other income (expense): Vesting [Axis] Statement of Financial Position [Abstract] Vesting [Domain] us-gaap_NonoperatingIncomeExpense Total other income, net Other income us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent crvo_GrantFundingRemaining Grant Funding Remaining Represents the amount of grant funding remaining. Nature of Operations [Text Block] Commercial Paper, Not Included with Cash and Cash Equivalents [Member] us-gaap_ProfessionalFees Professional fees us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-Based Payment Arrangement, Plan Modification, Incremental Cost Fair Value, Recurring [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount dei_DocumentType Document Type Operating expenses: Document Information [Line Items] Document Quarterly Report us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of shares (in shares) Commercial Paper [Member] Document Information [Table] us-gaap_DeferredRevenueCurrent Deferred Revenue, Current us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Antidilutive securities (in shares) us-gaap_OperatingLeaseExpense Operating Lease, Expense Antidilutive Securities [Axis] Exercisable, shares (in shares) dei_EntityInteractiveDataCurrent Entity Interactive Data Current us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Exercisable, weighted average exercise price per share (in dollars per share) Measurement Frequency [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Balance, number of shares (in shares) Outstanding, shares (in shares) Document Transition Report Commitments and Contingencies Disclosure [Text Block] Nature of Expense [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price per share (in dollars per share) Statement [Line Items] us-gaap_OperatingExpenses Total operating expenses Fair Value Hierarchy and NAV [Axis] Outstanding, aggregate intrinsic value us-gaap_CommonStockSharesIssued Common Stock, Shares, Issued (in shares) Per share information: us-gaap_CommonStockSharesOutstanding Common Stock, Shares, Outstanding (in shares) Award Type [Domain] Risk-free interest rate us-gaap_CommonStockSharesAuthorized Common Stock, Shares Authorized (in shares) Expected volatility Weighted average shares outstanding, basic and diluted (in shares) Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate crvo_ImpairmentOfMarketableSecurities Impairment of Marketable Securities Amount of impairment of marketable securities. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Net loss per share of common stock, basic and diluted (in dollars per share) Research and Development Expense, Policy [Policy Text Block] Other Current Liabilities [Table Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis. Common stock, $0.001 par value: 1,000,000,000 shares authorized at March 31, 2026 and December 31, 2025: 9,258,719 and 9,252,719 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Fair Value of Financial Instruments, Policy [Policy Text Block] Title and Position [Domain] Stock Option Vesting Terms As Improbable to Probable [Member] Represents stock options vesting terms as improbable to probable. Collaborative Arrangement and Arrangement Other than Collaborative [Table] Earnings Per Share, Policy [Policy Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Warrants, exercise price (in dollars per share) us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Accounts payable us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_TableTextBlock Notes Tables Document Fiscal Period Focus Document Fiscal Year Focus us-gaap_ComprehensiveIncomeNetOfTax Total comprehensive loss Amendment Flag Common Stock [Member] Maturities of marketable securities us-gaap_AccruedProfessionalFeesCurrent Professional fees Subsequent Events [Text Block] dei_DocumentPeriodEndDate Document Period End Date Granted, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Legal Entity [Axis] us-gaap_EmployeeRelatedLiabilitiesCurrent Employee compensation costs Significant Accounting Policies [Text Block] dei_EntityFileNumber Entity File Number us-gaap_SalesAndExciseTaxPayableCurrent State franchise and excise tax Balance, weighted average remaining contractual term (Year) Entity Tax Identification Number us-gaap_OtherAccruedLiabilitiesCurrent Total Entity [Domain] Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name crvo_PaymentsForLicenseAgreement Payments for License Agreement Amount of cash outflow for license agreement. Vertex Option and License Agreement [Member] Represents the Vertex Option and License Agreement. crvo_PolicyTable Fair Value, Assets Measured on Recurring Basis [Table Text Block] dei_EntityCurrentReportingStatus Entity Current Reporting Status crvo_ProceedsFromGrants Proceeds From Grants Amount of cash inflow from grants. National Institute of Aging Grant [Member] Represents National Institute of Aging Grant. Entity Incorporation, State or Country Code Expected term (in years) (Year) Current Fiscal Year End Date Exercisable, weighted average remaining contractual term (Year) crvo_AccruedClinicalStudiesExpensesCurrent Clinical development costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies. Research and development Research and Development Expense Entity Filer Category Clinical expenses Amount of prepaid clinical expenses. dei_EntityShellCompany Entity Shell Company Prepaid Expenses and Other Current Assets [Text Block] The entire disclosure for prepaid expenses and other current assets. Frontotemporal Disorders [Member] Represents the Frontotemporal disorders. Entity Emerging Growth Company Entity Small Business us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Amortized Cost us-gaap_OperatingIncomeLoss Loss from operations Cash and Cash Equivalents [Domain] Historical EIP Common Stock Warrants [Member] Represents Historical EIP common stock warrants. The 2018 Employee, Director and Consultant Equity Incentive Plan [Member] Represents the 2018 Employee, Director and Consultant Equity Incentive Plan. Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments Agreement, Maximum Deduction Percentage of Fees and Payments Percentage of maximum deduction of fees and payments under agreement. crvo_AgreementMilestonePeriodForNetSales Agreement, Milestone, Period for Net Sales The period for net sales that is used for milestone under the agreement. Grant revenue Revenues crvo_GrantAmountReceivedPercentage Grant Amount, Received, Percentage The total percentage amount of a grant received at the during the current period Entity Address, State or Province Statement of Stockholders' Equity [Abstract] Entity Address, City or Town us-gaap_RetainedEarningsAccumulatedDeficit Accumulated deficit Entity Address, Address Line One Class of Warrant or Right [Axis] Statement of Cash Flows [Abstract] Class of Warrant or Right [Domain] dei_CityAreaCode City Area Code dei_LocalPhoneNumber Local Phone Number Entity Address, Postal Zip Code Stockholders’ Equity: Title of 12(b) Security Equity Components [Axis] Security Exchange Name Trading Symbol us-gaap_GovernmentAssistanceAmountCumulative Government Assistance, Asset us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Convertible Preferred Stock [Member] Share-Based Payment Arrangement [Policy Text Block] us-gaap_GovernmentAssistanceAmount Government Assistance, Income, Increase (Decrease) Class of Stock [Axis] Proceeds from the exercise of stock options Equity Component [Domain] us-gaap_AvailableForSaleSecuritiesDebtSecurities Marketable securities Fair Value, Inputs, Level 2 [Member] Dementia with Lewy bodies [Member] Represents the research and development for Dementia with Lewy bodies. Fair Value, Inputs, Level 3 [Member] Revenue [Policy Text Block] AOCI Attributable to Parent [Member] Fair Value, Inputs, Level 1 [Member] Equity [Text Block] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Additional Paid-in Capital [Member] Warrants outstanding (in shares) Retained Earnings [Member] Other Research and Development Costs [Member] Represents the other research and development costs. Chief Operating Officer [Member] Personnel Costs [Member] Represents the personnel costs. Other us-gaap_OtherAssetsCurrent us-gaap_OtherSundryLiabilitiesCurrent Other Stock Based Compensation [Member] Represents the stock based compensation classified under the research and development. Recovery After Stroke [Member] Represents the research and development for recovery after stroke. Net unrealized loss on marketable securities Other Clinical and Nonclinical [Member] Represents the other clinical and nonclinical research and development. crvo_GrantFundingCanceled Grant Funding Canceled Represents the amount of grant funding canceled. Subsequent Event [Table] crvo_GrantAmountCanceledPercentage Grant Amount Canceled, Percentage Percentage of grant amount canceled. us-gaap_OtherGeneralAndAdministrativeExpense Other general and administrative expenses, including IT, facilities, supplies and similar costs*** Sale of Stock [Axis] Exercisable, aggregate intrinsic value us-gaap_CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share (in dollars per share) Stock-based compensation expense crvo_GrantFundingForfeited Grant Funding Forfeited Amount of grant funding forfeited. us-gaap_TaxesExcludingIncomeAndExciseTaxes Insurance, taxes and similar fees Basis of Accounting, Policy [Policy Text Block] Inducement Options [Member] Represents inducement options. Other expense Research and Development [Member] Represents research and development. crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees Number of employees affected by share-based payment arrangement. General and Administrative [Member] Represents general and administrative. Sale of Stock [Domain] Share-Based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_Assets Total assets Cash and Cash Equivalents, Policy [Policy Text Block] Deferred Charges, Policy [Policy Text Block] Cash and cash equivalents Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-Term Investments Share-Based Payment Arrangement, Option [Member] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Supplemental disclosure of non-cash investing and financing activities: Deferred offering costs Deferred Offering Costs crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease Share Based Compensation Arrangement By Share Based Payment Award, Number of Shares Available for Grant, Increase (in shares) Represents the increase in the number of shares available for grant under a share based compensation arrangement. Current liabilities: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion of discount on marketable securities, net The 2025 Equity Plan [Member] Represents 2025 Equity Plan. May 2025 At-the-market Offering [Member] Represents the May 2025 At-The-Market Offering. Marketable securities Legal Costs, Policy [Policy Text Block] Unrealized loss on marketable securities Consolidation, Policy [Policy Text Block] Interest income Accrued expenses and other current liabilities Represents the amount of liability of accrued expenses and other current liabilities recorded as of a point in time. Lessee, Leases [Policy Text Block] Other Commitments [Table] Accumulated other comprehensive (loss) income Interim Period, Costs Not Allocable [Domain] General and administrative Total general and administrative expenses Grant receivable us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional paid-in capital us-gaap_StockholdersEquity Total stockholders' equity Balance Balance Use of Estimates, Policy [Policy Text Block] us-gaap_PrepaidExpenseAndOtherAssetsCurrent Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period US Treasury Bond Securities [Member] Stock, Class of Stock [Table] Current assets: Exercise of stock options Money Market Funds [Member] us-gaap_AssetsCurrent Total current assets Fair Value, Recurring and Nonrecurring [Table] crvo_ShareSalesAgreementMaximumAmount Share Sales Agreement, Maximum Amount The maximum amount for share sales agreement. ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Commitments and Contingencies us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues Marketable Securities [Table Text Block]